Introduction {#s1}
============

High blood pressure (BP) is the leading cause of disease burden worldwide [@pone.0061796-Ezzati1]. Suboptimal BP is responsible for a huge economic and health burden in both developed and developing countries [@pone.0061796-Gaziano1]. Worldwide, more than seven million premature deaths can be attributed directly or indirectly to hypertension [@pone.0061796-Lawes1]. Complications of hypertension affect life quality substantially because many crucial organs, such as heart, brain and kidney, are involved and damaged. It has become an important public-health challenge to the world since the number of hypertensive people is extremely large [@pone.0061796-Kearney1].

The association between high BP and cardiovascular disease (CVD) and mortality is well established [@pone.0061796-Lewington1]--[@pone.0061796-He2]. BP is strongly related to vascular mortality, down to at least 115/75 mm Hg [@pone.0061796-Lewington1]. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) timely updated the BP category, coming up with the concept of prehypertension for better management [@pone.0061796-Chobanian1]. Numerous studies emerged afterward to investigate the risk of prehypertension for various types of adverse outcomes, including stroke, coronary heart disease, and CVD and all-cause mortality [@pone.0061796-Vasan1]--[@pone.0061796-Carlsson1].

Risk of mortality provides evidence for the prevention and treatment strategies of prehypertension. Since the ultimate public health goal of antihypertensive therapy is to reduce cardiovascular or total mortality, it is important to recognize first how risky prehypertension is for CVD or total death. Although a few studies pertaining to this issue exist, the conclusion has been compromised by the inconsistent results. It is difficult to assess this issue in a single study due to limited events. To our knowledge, there has been no quantitative analysis conducted to investigate the relationship between prehypertension and CVD or all-cause mortality from the literature worldwide. Therefore, we performed this meta-analysis to characterize the magnitude of these associations on a prospective level.

Materials and Methods {#s2}
=====================

Literature Search {#s2a}
-----------------

We performed and reported a systematic review of the published literature according to the recommendations of the Meta-analysis of Observational Studies in Epidemiology Group [@pone.0061796-Stroup1] and the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Statement [@pone.0061796-Moher1]. We conducted a comprehensive search of PubMed (1966-June 2012) and the Cochrane Library (1988-June 2012) without language restrictions. Search terms including MeSH words and text words were related to exposure ("prehypertensi\*" or \"high normal blood pressure\") and to outcomes ("mortality", "survival", "death" or "fatal"). Two authors (Guo X and Zhang XY) independently screened the studies fulfilling the inclusion criteria. In addition, we manually searched the references in the articles chosen for data abstraction and in the relevant reviews identified in the search. If the articles did not contain all of the necessary information, we contacted the authors for any possible additional published or unpublished data.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

For inclusion, studies had to meet the following criteria: (1) original article, prospective cohort design; (2) assessment of prehypertension or high normal BP as baseline exposure; (3) assessment of CVD mortality or all-cause mortality as outcome; (4) follow-up of at least 5 years, and (5) reported association measures \[relative risk (RR) or hazard ratio (HR) and 95% confidence interval (95% CI)\] from the multivariate-adjusted analyses between exposure and outcomes with normal BP as reference. Multiple samples with different gender, age or ethnic groups based on the same population were also included. If multiple reports from the same study were identified, we used the one with the most detailed information and supplemented it.

Studies were excluded if they met the following criteria: (1) no original data (reviews, comments); (2) only unadjusted or age- and gender-adjusted RR or HR was reported; (3) duplicated studies; (4) not conducted in human, and (5) data were derived from secondary analysis of clinical trials.

Data Extraction {#s2c}
---------------

Using a standardized data extraction form, two investigators (Guo L and Li Z) extracted the data independently with discrepancies resolved by an additional reviewer (Zheng L) and through discussion. Information extracted included first author's name, publication year, country, sample characteristics, prevalence of prehypertension, follow-up, definition of high BP, adjusted variables, outcome assessment, and multivariate-adjusted RRs or HRs and corresponding 95% CIs. An electronic abstraction database was created in Microsoft Excel.

Assessment of Study Quality {#s2d}
---------------------------

According to the guidelines developed by the US Preventive Task Force and the modified checklist used in previous studies [@pone.0061796-Harris1]--[@pone.0061796-Lee1], we assessed quality of all articles that met the selection criteria with the following eight items: (1) prospective study design; (2) maintenance of comparable groups; (3) adjustment of potential confounders; (4) documented loss of follow-up rate; (5) outcome assessed blind to exposure status; (6) clear and proper definition of exposures (prehypertension) and outcomes (CVD and all-cause mortality); (7) temporality (BP measured at baseline, not at time of outcomes assessment) and (8) follow-up of at least one year. Studies were graded as of good quality if they met 7 to 8 criteria; fair if they met 4 to 6; and poor if they met fewer than 4 criteria.

Statistical Analyses {#s2e}
--------------------

Prehypertension was defined as systolic blood pressure (SBP) at 120--139 mmHg or diastolic blood pressure (DBP) at 80--89 mmHg, with two BP ranges further divided (i.e. low range: SBP 120--129 mmHg or DBP 80--84 mmHg and high range: SBP 130--139 mmHg or DBP 85--89 mmHg). Normal BP (SBP\<120 mmHg and DBP\<80 mmHg) was taken as the reference category for RRs. Outcome assessment was the relative risk of CVD and all-cause mortality in the low-range and high-range prehypertension categories, respectively or in the whole prehypertensive range.

To estimate quantitative associations between prehypertension and the mortality outcomes, we obtained pooled estimates basing on the multivariate-adjusted RRs or HRs with 95% CIs from included studies. Between-study heterogeneity was evaluated by Q-statistic and quantified by the I^2^ statistic. I^2^ statistic of 0%--40% indicates unimportant heterogeneity, 30%--60% indicates moderate heterogeneity, 50%--90% indicates substantial heterogeneity, and 75%--100% indicates considerable heterogeneity [@pone.0061796-Higgins1]. If statistically significant heterogeneity was considered present (P\<0.1 and I^2^\>50%), we chose a random-effects model, otherwise, a fixed-effects model was used. Subgroup analyses were performed to explore the heterogeneity according to average age (\<65 years vs. ≥65 years), gender (men vs. women), location (Asian vs. non-Asian), sample size (\<10000 vs. ≥10000), follow-up (\<10 years vs. ≥10 years) and study quality (good vs. fair). Possible publication bias was evaluated visually using funnel plots and statistically by Begg's and Egger's tests. Sensitivity analysis was used to examine the influence of individual studies to see the extent to which inferences depend on a particular study or group of studies. All analyses were performed using the statistical package Stata version 11.0.

Results {#s3}
=======

Search Results {#s3a}
--------------

A total of 1022 papers were identified from the initial database search, of which 984 were excluded following review of the title and abstract. The large majority of articles were excluded because they were not relevant to the issue we aimed to evaluate. Among the retrieved 38 articles, 13 cohort studies met our inclusion criteria, with 870,678 participants [@pone.0061796-Mainous1]--[@pone.0061796-Gombojav1]. [Figure 1](#pone-0061796-g001){ref-type="fig"} provides a diagram of the selection process and reasons for exclusion.

![Flow chart of the study selection process.](pone.0061796.g001){#pone-0061796-g001}

Study Characteristics {#s3b}
---------------------

[Table 1](#pone-0061796-t001){ref-type="table"} summarizes the characteristics of the individual studies. The included studies varied in sample size from 2376 [@pone.0061796-Kim1] to 347,978 [@pone.0061796-Terry1]. All but three of the studies [@pone.0061796-Terry1], [@pone.0061796-Hsia1], [@pone.0061796-Dorjgochoo1] included both men and women. Follow-up ranged from 5 to 25 years. Five of the studies were conducted in the United States, two each in China, Korea and Japan, and one each in India and Singapore. We restricted the inclusion criteria to prospective studies with at least a minimum of 5 years follow-up to ensure a reliable conclusion. Eight of the included articles had good study quality.

10.1371/journal.pone.0061796.t001

###### Description of characteristics from prospective studies included in the systematic review and meta-analysis.

![](pone.0061796.t001){#pone-0061796-t001-1}

  First author, Publication year                                            Study                      Country      Prevalence (pre-HTN)              Sample size (% men)               Follow-up (y)   Age, y (mean, range or SD)        Definition of pre-HTN                                                                                              Adjusted variables                                                                                        Studyquality
  --------------------------------------------------------- -------------------------------------- --------------- ---------------------- -------------------------------------------- --------------- ---------------------------- ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------
  Arch G. Mainous III,2004 [@pone.0061796-Mainous1]            NHANES II, merged with the NH2MS     United States          28.7%                            9087(NA)                         12                   30--74                          JNC 7                                                             Age, race, sex, smoking, BMI, exercise,total cholesterol, DM, heartfailure, heart attack and stroke                                                    Fair
  Paul D. Terry, 2006 [@pone.0061796-Terry1]                                MRFIT                   United States            NA                           347978(100)                        25                   35--57                          JNC 7                                                                  Age, race/ethnicity, income, serum cholesterol level, smoking and use of medication for DM                                                        Fair
  Judith Hsia, 2007 [@pone.0061796-Hsia1]                                    WHI                    United States          38.8%                            60785(0)                         7.7                 62.8 (7)                     JNC 7 or JNC 6                                                                                     Age, BMI, DM, high cholesterol and smoking                                                                                Good
  Qiuping Gu, 2008 [@pone.0061796-Gu1]                            NHANES III mortality study        United States          30.8%                           16917(42)                         8.5                   ≥18                            JNC 7                 Age, sex, race/ethnicity, leisure timephysical activity, smoking, obesity,hypercholesterolemia, DM, chronic kidney disease, and a history of congestiveheart failure, heart attack or stroke       Good
  Jeannette Lee, 2008 [@pone.0061796-Lee2]                   Singapore CardiovascularCohort Study     Singapore            28.5%                            5830(49)                         12           39.8 (12.9)for pre-HTN                  JNC 7                                                          Age, sex, BMI, ethnic group, total-cholesterol/HDL-cholesterol, study, DM, CVD, smoking and alcohol intake                                                Good
  Dongfeng Gu, 2009 [@pone.0061796-Gu2]                       China National HypertensionSurvey         China              34.5%                           158666(49)                        7.8                 56 (≥40)                         JNC 7                           Age, sex, high school education,smoking, alcohol consumption, physical activity,BMI, antihypertensive medication, history ofCVD or DM, geographic region andurbanization                 Good
  Ai Ikeda, 2009 [@pone.0061796-Ikeda1]                                   JPHC Study                    Japan              43.0%                           33372(35)                         11                54 (40--69)               2003 European guidelines                                    Age, BMI, smoking, ethanol intake, antihypertensive medication, DM, serum total cholesterol levels and public health center areas                                     Good
  Mangesh S. Pednekar,2009 [@pone.0061796-Pednekar1]                    Mumbai cohort                   India              38.8%                           148173(59)                        5.5                 50 (≥35)                         JNC 7                                                                                Age, education, religion, mother tongue, tobacco habit and BMI                                                                      Fair
  Tsogzolmaa Dorjgochoo, 2009 [@pone.0061796-Dorjgochoo1]       Shanghai Women's Health Study           China              39.0%                           68438 (0)                          5                55 (40--70)           JNC 7 or 2007 Europeanguidelines                                                                  Education, waist-to-hip ratio, smoking, history of CVD and DM                                                                       Fair
  Carlos Lorenzo, 2009 [@pone.0061796-Lorenzo1]                    San Antonio Heart Study          United States          31.6%           3632 for all cause, 3580 for CVD mortality       15.2                  25--64                      JNC 7 or JNC 6                                                                  Age, sex, ethnicity, education, BMI, smoking and total cholesterol concentration                                                             Good
  Atsushi Hozawa, 2009 [@pone.0061796-Hozawa1]                       Ohsaki Cohort Study                Japan              41.8%                           12928(43)                        11.7                61.2 (9.4)                        JNC 7                                                                                 Age, sex, smoking, hyperglycemia, total cholesterol and BMI                                                                        Good
  Nan Hee Kim, 2011 [@pone.0061796-Kim1]                                  SWS Study                     Korea              28.7%                            2376(22)                         7.6                   \>60              JNC 7 or 2007 Europeanguidelines                                                                Age, sex, BMI, fasting glucose, HDL, total cholesterol and smoking                                                                    Good
  Bayasgalan Gombojav, 2011 [@pone.0061796-Gombojav1]              The Kangwha Cohort Study             Korea                NA                            2496(42.3)                       11.8                 64--101                          JNC 7                                     Age, education, smoking, drinking, activities of daily living, instrumental activities of daily living, chronic disease and antihypertensive therapy                           Good

Pre-HTN: prehypertension; NA: not available; SD:standard deviation; BMI: body mass index; DM: diabetes mellitus; CVD: cardiovascular disease; HDL: high density lipoprotein. JNC 7: prehypertension (120--139/80 --89 mmHg); JNC 6, 2003 European guidelines and 2007 European guidelines: high normal blood pressure (130--139/85--89 mmHg) and normal blood pressure (120--129/80--84 mmHg).

Prehypertension and All-cause Mortality {#s3c}
---------------------------------------

In the pooled analysis from 8 populations, both low-range and high-range prehypertension were not associated with a greater risk of all-cause mortality (low-range: RR: 0.91; 95% CI: 0.81 to 1.02, *P* = 0.107; high range: RR: 1.00; 95% CI: 0.95 to 1.06, *P* = 0.951) ([Figure 2a and b](#pone-0061796-g002){ref-type="fig"}). Seven studies investigated the association between the whole range of prehypertension and all-cause mortality, the pooled result of which showed that prehypertension was not related to a greater risk of all-cause mortality (RR: 1.03; 95% CI: 0.91 to 1.15, *P* = 0.667), with some heterogeneity between studies (I^2^ = 46.5%, *P* = 0.07) ([Figure 3](#pone-0061796-g003){ref-type="fig"}).

![Association between two ranges of prehypertension, low range (a) and high range (b), and the risk of all-cause mortality.\
Low range prehypertension: 120--129/80--84 mmHg; high range prehypertension: 130--139/85--89 mmHg. CI: confidence interval.](pone.0061796.g002){#pone-0061796-g002}

![Association between prehypertension and the risk of all-cause mortality.\
CI: confidence interval.](pone.0061796.g003){#pone-0061796-g003}

Prehypertension and Cardiovascular Disease Mortality {#s3d}
----------------------------------------------------

Seven studies with nine populations evaluated the risk of low-range and high-range prehypertension for CVD mortality separately. Only high range prehypertension was associated with an increased risk of CVD mortality (low-range: RR: 1.10; 95% CI: 0.92 to 1.30, *P* = 0.287; high range: RR: 1.26; 95% CI: 1.13 to 1.41, *P*\<0.001) ([Figure 4a and b](#pone-0061796-g004){ref-type="fig"}). Among the whole range prehypertensive populations, the risk of CVD mortality was also increased (RR: 1.32; 95% CI: 1.16 to 1.50, *P*\<0.001) ([Figure 5](#pone-0061796-g005){ref-type="fig"}), with some heterogeneity between studies (I^2^ = 74.4%, *P*\<0.001).

![Association between two ranges of prehypertension, low range (a) and high range (b), and the risk of CVD mortality.\
Low range prehypertension: 120--129/80--84 mmHg; high range prehypertension: 130--139/85--89 mmHg. CI: confidence interval; CVD: cardiovascular disease.](pone.0061796.g004){#pone-0061796-g004}

![Association between prehypertension and the risk of CVD mortality.\
CI: confidence interval; CVD: cardiovascular disease.](pone.0061796.g005){#pone-0061796-g005}

Sources of Heterogeneity {#s3e}
------------------------

[Table 2](#pone-0061796-t002){ref-type="table"} shows the further analyses stratified by various population groups in each range of prehypertension. The heterogeneity of effect was due to differences in gender, age, follow-up or study quality. No publication bias was observed (Begg's test all *P*\>0.05; Egger's test all *P*\>0.05, figures not shown). The sensitivity analysis showed that the omission of any of the studies from the analysis did not alter the overall finding.

10.1371/journal.pone.0061796.t002

###### Subgroup analyses to explore source of heterogeneity.

![](pone.0061796.t002){#pone-0061796-t002-2}

  Subgroups                                                CVD mortality   All-cause mortality                              
  ------------------------------------------------------- --------------- --------------------- --- -------------------- -- --
  **Low range (SBP 120--129 mmHg or DBP 80--84 mmHg)**                                                                      
  **Gender**                                                                                                                
  Men                                                            3          1.11 (0.97--1.28)    2   1.03 (0.78--1.37)      
  Women                                                          4          1.13 (0.72--1.75)    3    0.822 (0.72--1)       
                                                                                  0.46                     0.014            
  **Age group**                                                                                                             
  ≥65 y                                                          3          0.82 (0.57--1.19)    1    0.8 (0.48--1.33)      
  \<65 y                                                         8          1.14 (0.93--1.41)    7   0.92 (0.81--1.03)      
                                                                                  0.146                    0.679            
  **Location**                                                                                                              
  Asian                                                          5          0.99 (0.77--1.26)    6    0.9 (0.79--1.02)      
  Non-Asian                                                      4          1.27 (1.03--1.58     2   0.99 (0.67--1.46)      
                                                                                  0.09                     0.424            
  **Sample size**                                                                                                           
  \<10000                                                        3          1.13 (0.82--1.55)    3   0.94 (0.71--1.24)      
  ≥10000                                                         6          1.09 (0.88--1.36)    5    0.9 (0.79--1.03)      
                                                                                  0.811                    0.582            
  ** Follow-up**                                                                                                            
  \<10 y                                                         5          1.07 (0.82--1.4)     4   0.84 (0.74--0.94)      
  ≥10 y                                                          4          1.16 (0.9--1.49)     4   1.04 (0.86--1.25)      
                                                                                  0.573                    0.011            
  ** Study quality**                                                                                                        
  Good                                                           6          1.31 (1.06--1.61)    4    1.07 (0.9--1.27)      
  Fair                                                           3          0.93 (0.69--1.26)    4   0.84 (0.75--0.94)      
                                                                                  0.037                    0.005            
  **High range (SBP 130--139 mmHg or DBP 85--89 mmHg)**                                                                     
  ** Gender**                                                                                                               
  Men                                                            3           1.2 (1.04--1.4)     2    1.02 (0.94--1.1)      
  Women                                                          4          1.33 (1.09--1.62)    3   0.94 (0.85--1.04)      
                                                                                  0.443                    0.242            
  ** Age group**                                                                                                            
  ≥65 y                                                          3          0.84 (0.59--1.21)    1   1.35 (0.84--2.18)      
  \<65 y                                                         8          1.27 (1.13--1.43)    7   0.997 (0.94--1.06)     
                                                                                  0.034                    0.217            
  ** Location**                                                                                                             
  Asian                                                          5          1.19 (1.04--1.36)    6   0.99 (0.94--1.06)      
  Non-Asian                                                      4          1.44 (1.18--1.75)    2   1.11 (0.89--1.39)      
                                                                                  0.113                    0.344            
  ** Sample size**                                                                                                          
  \<10000                                                        3          1.34 (0.99--1.83)    3   1.15 (0.94--1.41)      
  \>10000                                                        6          1.25 (1.11--1.41)    5   0.99 (0.93--1.05)      
                                                                                  0.678                    0.159            
  ** Follow-up**                                                                                                            
  \<10 y                                                         5          1.24 (1.09--1.4)     4   0.98 (0.92--1.04)      
  \>10 y                                                         4          1.36 (1.07--1.74)    4   1.11 (0.97--1.27)      
                                                                                  0.486                     0.09            
  ** Study quality**                                                                                                        
  Good                                                           6          1.49 (1.23--1.8)     4   1.18 (1.02--1.36)      
  Fair                                                           3          1.16 (1.01--1.33)    4   0.97 (0.91--1.04)      
                                                                                  0.035                    0.018            

CVD: cardiovascular disease; RR: relative risk; CI: confidence interval;

SBP: systolic blood pressure; DBP: diastolic blood pressure.

Discussion {#s4}
==========

The present study provided for the first time a comprehensive review of the literature and quantitative estimates of prospective associations between prehypertension and CVD and all-cause mortality. We found that prehypertension, including both ranges, was not associated with all-cause mortality. The positive association between prehypertension and the risk of CVD mortality was confined to the high range BP group when analyzed by two ranges separately. The effects of prehypertension on mortality differed by many factors, such as age group, sample size and study quality.

A high prevalence of prehypertension was observed in many areas of the world [@pone.0061796-Isezuo1]--[@pone.0061796-Gupta1]. In the United States, the overall prevalence of prehypertension was approximately 31% according to the Third National Health and Nutrition Examination Survey (NHANES III) [@pone.0061796-Wang1], and 3 of 8 adults had low range prehypertension and 1 of 8 adults had high range prehypertension from 2005 to 2006 [@pone.0061796-Egan1]. Considering this large population and the high progression rate from prehypertension to hypertension, the burden is large.

A previous meta-analysis of 61 prospective studies indicated that the risk of cardiovascular mortality began to increase from BP values of 115/75 mmHg, and doubled for each 20 mmHg rise in SBP and 10 mmHg rise in DBP among 40--69-year-olds [@pone.0061796-Lewington1], suggesting that a BP range of 115--140/75--90 mmHg might also cause adverse outcomes and merits attention. In the present study, we quantitatively estimated that the risk of CVD mortality was increased ∼1.3-fold in the prehypertensive range compared to normal BP, the risk ratio of which was lower than the result by Lewington et al [@pone.0061796-Lewington1]. This might be explained by the various age groups included. When the data were analyzed by two BP ranges separately, we found that only high range prehypertension was related to a greater risk of CVD mortality. Although the relatively small number of deaths in the low range BP group is an alternative explanation, this is in accordance with the higher risk of CVD morbidity or mortality in the BP range of 130--139/85--89 mmHg described in previous studies [@pone.0061796-Vasan2]--[@pone.0061796-Conen1], underscoring the differences between the two BP ranges of prehypertension.

Interestingly, we found that there was no relationship between prehypertension or either of its two ranges and all-cause mortality. Although a previous pooled study of Japanese subjects indicated that prehypertension was significantly associated with all-cause mortality following multivariate-adjustment, the positive result was mild and limited to only two decades of age [@pone.0061796-Murakami1]. There might exists an age- or gender-specific relationship which our study failed to reach, but it seems plausible that there is no real association between prehypertension and all-cause mortality.

We assumed that the inconsistent results between CVD mortality and all-cause mortality we observed in the present study might be caused by the different data set included in the two analyzing groups. Previous studies showed that the relation of BP to CVD mortality or all-cause mortality was closely associated with age [@pone.0061796-Lewington1], [@pone.0061796-Murakami1]. Although the studies we included were all age-adjusted, the different age distributions in the two analyzing data set may still have an effect on the outcomes. In addition, there were many other causes of mortality, such as cancer or accidental death, which might decrease in proportion to CVD mortality. For example, Terry et al reported that the rate of all external death was 4.95% in normal BP group, compared to a lower one of 4.47% in prehypertension group [@pone.0061796-Terry1].

Lifestyle modifications have been shown to effectively lower BP and are regarded as the first choice for prehypertension management. Although a few studies have demonstrated good efficacy and safety of antihypertensive treatment for prehypertension [@pone.0061796-Julius1]--[@pone.0061796-Sipahi1], it is not known whether the benefits of pharmacological therapy outweigh the harms. Our data provide evidence for the establishment of prevention and treatment strategies of prehypertension. Different effects of two BP ranges in prehypertension on future outcomes should be fully considered.

There are limitations in the present study that merit discussion. First, the contributing studies varied in their initial exclusion criteria and their inclusion of adjustment confounders. Although we only included multivariate-adjusted studies to minimize the impact, it remains a possibility that residual confounding across the studies caused overestimation of the associations. Second, since individual patient data or original data were unavailable, our intent to do more detailed relevant analyses, such as analysis by each decade of age, was restricted. In addition, a delay between search and publication was inevitable. Although our literature search was extensive, there still was a possibility of omission.

Conclusions {#s5}
===========

From the best available prospective data, prehypertension was not associated with all-cause mortality. More high quality cohort studies stratified by BP range are needed. Different effects of two ranges in prehypertension on future outcomes should be fully considered when making prevention and treatment strategies.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the research: YS JL XG. Screened the studies: XG Xiaoyu Zhang L. Zheng. Extracted the data: LG ZL L. Zheng. Assessed study quality: L. Zou Xingang Zhang ZS JL. Analyzed the data: XG SY HY Xinghu Zhou. Wrote the paper: XG Xiaoyu Zhang YS.
